Shirt a Phobia

Sample Page

Adrogolide (INNTooltip International Nonproprietary Name; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride (USANTooltip United States Adopted Name) in the case of the hydrochloride salt, is a dopamine D1-like receptor agonist which was under development for the treatment of Parkinson’s disease, cognition disorders, and cocaine-related disorders but was never marketed.[2][3][4][1][5]

It is a chemically stable and rapidly converted diacetate ester prodrug of the highly selective dopamine D1 and D5 receptor full agonist A-86929.[1] The effects of adrogolide and A-86929 in animals and humans have been studied.[1][5] Side effects of adrogolide in humans included injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness.[1]

Adrogolide was under development by Abbott Laboratories and DrugAbuse Sciences.[2][3][4] It reached phase 2 clinical trials for Parkinson’s disease prior to the discontinuation of its development in 2001.[2][3][4] The drug is said to have been the first extensively characterized dopamine D1 receptor full agonist.[1]

See also

References

  1. ^ a b c d e f g h i j k l Giardina WJ, Williams M (2001). “Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data”. CNS Drug Rev. 7 (3): 305–316. doi:10.1111/j.1527-3458.2001.tb00201.x. PMC 6741696. PMID 11607045.
  2. ^ a b c “Adrogolide”. AdisInsight. 30 January 2013. Retrieved 1 February 2026.
  3. ^ a b c “Delving into the Latest Updates on Adrogolide Hydrochloride with Synapse”. Synapse. 15 November 2025. Retrieved 1 February 2026.
  4. ^ a b c “Adrogolide Drug Profile”. Ozmosi. 1 January 1900. Retrieved 1 February 2026.
  5. ^ a b Unattributed (2000). “Information Update Volume 1-24, Number 8”. Drugs of the Future. 25 (8): 843–888 (844–844). ABT-431. Adrogolide Hydrochloride […]